Company profilePharmaceutical#393 of 1,318 in Pakistan✓ No DRAP alerts

BF Biosciences Limited

Pharmaceutical company · 42 brands · 32 molecules

Ranked #49 of 60 companies in Antithrombotic Agents

42 registered products 29 pharmaceutical brands 32 distinct molecules 0 DRAP alerts

Company overview

42
registered products
29
pharmaceutical brands
32
distinct molecules
4
therapeutic classes
0
DRAP alerts

BF Biosciences Limited is a pharmaceutical manufacturer registered with the Drug Regulatory Authority of Pakistan, holding 42 product registrations across 32 distinct molecules. Its portfolio is concentrated in Antithrombotic Agents and Antimycotics Systemic Use. It has no DRAP recall, shortage or safety notices on record.

Compiled from the DRAP registry, DRAP approved prices and DRAP alerts, with observed retail from DVAGO and Servaid. Data as of 2026-07-30.

Products by BF

14 products matched in our catalogue — each with its observed price and DRAP approved ceiling.

Price ceiling age

DRAP sets a maximum price per registration and revises it only on application. In a market with high inflation, an old ceiling erodes margin in real terms.

14
ceilings with an approval date
0
not revised in 2+ years
2026
oldest approval year
202614

Top molecules by brand count

Therapeutic classes

Antithrombotic Agents · 1Antimycotics Systemic Use · 1Anti-Infectives · 1Antiemetics & Antinauseants · 1

Conditions treated

Fungal Infection · 1

Price band (DRAP official ceilings)

Registered products priced by source
DRAP-official49 products · Rs 23.76 – Rs 59,411.34
DVAGO1 products · Rs 2,053.7 – Rs 2,053.7
Servaid1 products · Rs 1,199.9 – Rs 1,199.9
Median across source: Rs 2,053.7

Regulatory record

No DRAP alerts on record

No recalls, shortage notices or safety alerts involving this company’s products appear in the DRAP alert feed we track. Median across all 1,318 mapped companies is zero — 1,165 of them also have a clean sheet.

Competitive set

Companies whose registered portfolio overlaps most with this one.

Portfolio whitespace

Molecules the closest competitors have registered and this company has not — the starting point for a launch shortlist.

SAMI PHARMACEUTICALS (PVT) LTD. holds 169 molecules not in this portfolio
000 I.UAceclofenacAlprazolamAmikacinAmlodipineAnastrozole
MACTER INTERNATIONAL (PVT) LTD. holds 177 molecules not in this portfolio
000 I.U10Ug Polysaccharides Covalently Bound To 20Ug To 32Ug Of Tetanus ToxoidAlbendazoleAlbuterolAlfacalcidolAluminium Hydroxide
GETZ PHARMA PAKISTAN (PVT) LTD. holds 271 molecules not in this portfolio
),Formoterol3 ) 20Mg} Folic AcidAcetazolamideAcyclovirAdrenalineAlbendazole

Get the full profile for BF

This page is a summary. The full company brief adds every registration with its approved ceiling and approval date, per-molecule competitive position, price positioning against the category, and a launch shortlist built from the whitespace above.

Request this brief See what’s included

Company data as of 2026-07-30. Brand and molecule counts from the DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.